Which has stronger earnings and valuation, OCGN or MRNA?

Ocugen has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ocugen $4.41M 106.89 -$67.85M -$0.26 N/A Moderna $1.94B 29.79 -$2.82B -$7.99 N/A

Is OCGN or MRNA more profitable?

Ocugen has a net margin of 0.00% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Ocugen N/A -127,987.80% -115.95% Moderna -141.43% -28.30% -19.39%

Which has preferable earnings & valuation, OCGN or PFE?

Pfizer has higher revenue and earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ocugen $4.41M 106.89 -$67.85M -$0.26 N/A Pfizer $62.58B 2.55 $7.77B $0.76 36.84

Is OCGN or PFE more profitable?

Pfizer has a net margin of 6.80% compared to Ocugen's net margin of 0.00%. Pfizer's return on equity of 19.63% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Ocugen N/A -127,987.80% -115.95% Pfizer 6.80% 19.63% 8.46%

Which has better valuation and earnings, OCGN or IMCR?

Immunocore has higher revenue and earnings than Ocugen. Immunocore is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ocugen $4.41M 106.89 -$67.85M -$0.26 N/A Immunocore $400.02M 4.75 -$35.51M -$0.37 N/A

Is OCGN or IMCR more profitable?

Ocugen has a net margin of 0.00% compared to Immunocore's net margin of -4.20%. Immunocore's return on equity of -4.54% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Ocugen N/A -127,987.80% -115.95% Immunocore -4.20% -4.54% -1.66%

Which has better earnings and valuation, ANAB or OCGN?

AnaptysBio has higher revenue and earnings than Ocugen. AnaptysBio is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AnaptysBio $234.60M 7.29 -$13.23M -$1.08 N/A Ocugen $4.41M 106.89 -$67.85M -$0.26 N/A

Is ANAB or OCGN more profitable?

Ocugen has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%. AnaptysBio's return on equity of 0.00% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets AnaptysBio -11.53% N/A -7.75% Ocugen N/A -127,987.80% -115.95%

Ocugen (OCGN) Competitors

$1.39 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Compare

OCGN vs. MRNA, PFE, IMCR, RXRX, and ANAB

Should you buy Ocugen stock or one of its competitors? Ocugen's main competitors and comparable companies include Moderna (MRNA), Pfizer (PFE), Immunocore (IMCR), Recursion Pharmaceuticals (RXRX), and AnaptysBio (ANAB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Ocugen compare to Moderna?

Ocugen (NASDAQ:OCGN) and Moderna (NASDAQ:MRNA) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

In the previous week, Moderna had 114 more articles in the media than Ocugen. MarketBeat recorded 114 mentions for Moderna and 0 mentions for Ocugen. Moderna's average media sentiment score of 0.38 beat Ocugen's score of 0.00 indicating that Moderna is being referred to more favorably in the news media.

Company	Overall Sentiment
Ocugen	Neutral
Moderna	Neutral

Ocugen has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.41M	106.89	-$67.85M	-$0.26	N/A
Moderna	$1.94B	29.79	-$2.82B	-$7.99	N/A

10.3% of Ocugen shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 4.0% of Ocugen shares are held by insiders. Comparatively, 10.8% of Moderna shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Ocugen presently has a consensus price target of $9.50, suggesting a potential upside of 583.45%. Moderna has a consensus price target of $69.50, suggesting a potential downside of 52.09%. Given Ocugen's stronger consensus rating and higher probable upside, research analysts clearly believe Ocugen is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Moderna	4 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.00

Ocugen has a beta of 2.21, suggesting that its share price is 121% more volatile than the broader market. Comparatively, Moderna has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market.

Ocugen has a net margin of 0.00% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocugen	N/A	-127,987.80%	-115.95%
Moderna	-141.43%	-28.30%	-19.39%

Summary

Ocugen and Moderna tied by winning 7 of the 14 factors compared between the two stocks.

How does Ocugen compare to Pfizer?

Ocugen (NASDAQ:OCGN) and Pfizer (NYSE:PFE) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

Ocugen currently has a consensus price target of $9.50, suggesting a potential upside of 583.45%. Pfizer has a consensus price target of $28.28, suggesting a potential upside of 0.99%. Given Ocugen's stronger consensus rating and higher possible upside, equities analysts clearly believe Ocugen is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Pfizer	2 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.19

Pfizer has higher revenue and earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.41M	106.89	-$67.85M	-$0.26	N/A
Pfizer	$62.58B	2.55	$7.77B	$0.76	36.84

Pfizer has a net margin of 6.80% compared to Ocugen's net margin of 0.00%. Pfizer's return on equity of 19.63% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocugen	N/A	-127,987.80%	-115.95%
Pfizer	6.80%	19.63%	8.46%

Ocugen has a beta of 2.21, meaning that its share price is 121% more volatile than the broader market. Comparatively, Pfizer has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market.

10.3% of Ocugen shares are held by institutional investors. Comparatively, 68.4% of Pfizer shares are held by institutional investors. 4.0% of Ocugen shares are held by insiders. Comparatively, 0.6% of Pfizer shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Pfizer had 91 more articles in the media than Ocugen. MarketBeat recorded 91 mentions for Pfizer and 0 mentions for Ocugen. Pfizer's average media sentiment score of 0.91 beat Ocugen's score of 0.00 indicating that Pfizer is being referred to more favorably in the news media.

Company	Overall Sentiment
Ocugen	Neutral
Pfizer	Positive

Summary

Pfizer beats Ocugen on 10 of the 15 factors compared between the two stocks.

How does Ocugen compare to Immunocore?

Ocugen (NASDAQ:OCGN) and Immunocore (NASDAQ:IMCR) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability, media sentiment and institutional ownership.

Ocugen has a net margin of 0.00% compared to Immunocore's net margin of -4.20%. Immunocore's return on equity of -4.54% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocugen	N/A	-127,987.80%	-115.95%
Immunocore	-4.20%	-4.54%	-1.66%

Ocugen currently has a consensus target price of $9.50, indicating a potential upside of 583.45%. Immunocore has a consensus target price of $56.38, indicating a potential upside of 52.86%. Given Ocugen's stronger consensus rating and higher probable upside, research analysts plainly believe Ocugen is more favorable than Immunocore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Immunocore	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.58

In the previous week, Immunocore had 3 more articles in the media than Ocugen. MarketBeat recorded 3 mentions for Immunocore and 0 mentions for Ocugen. Immunocore's average media sentiment score of 0.28 beat Ocugen's score of 0.00 indicating that Immunocore is being referred to more favorably in the news media.

Company	Overall Sentiment
Ocugen	Neutral
Immunocore	Neutral

10.3% of Ocugen shares are owned by institutional investors. Comparatively, 84.5% of Immunocore shares are owned by institutional investors. 4.0% of Ocugen shares are owned by company insiders. Comparatively, 10.1% of Immunocore shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Ocugen has a beta of 2.21, meaning that its share price is 121% more volatile than the broader market. Comparatively, Immunocore has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market.

Immunocore has higher revenue and earnings than Ocugen. Immunocore is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.41M	106.89	-$67.85M	-$0.26	N/A
Immunocore	$400.02M	4.75	-$35.51M	-$0.37	N/A

Summary

Immunocore beats Ocugen on 10 of the 16 factors compared between the two stocks.

How does Ocugen compare to Recursion Pharmaceuticals?

Ocugen (NASDAQ:OCGN) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership.

In the previous week, Recursion Pharmaceuticals had 4 more articles in the media than Ocugen. MarketBeat recorded 4 mentions for Recursion Pharmaceuticals and 0 mentions for Ocugen. Recursion Pharmaceuticals' average media sentiment score of 0.69 beat Ocugen's score of 0.00 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Ocugen	Neutral
Recursion Pharmaceuticals	Positive

Ocugen has higher earnings, but lower revenue than Recursion Pharmaceuticals. Ocugen is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.41M	106.89	-$67.85M	-$0.26	N/A
Recursion Pharmaceuticals	$74.68M	25.09	-$644.76M	-$1.04	N/A

Ocugen presently has a consensus price target of $9.50, indicating a potential upside of 583.45%. Recursion Pharmaceuticals has a consensus price target of $8.06, indicating a potential upside of 130.29%. Given Ocugen's stronger consensus rating and higher possible upside, analysts clearly believe Ocugen is more favorable than Recursion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

10.3% of Ocugen shares are owned by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 4.0% of Ocugen shares are owned by company insiders. Comparatively, 6.7% of Recursion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Ocugen has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -945.94%. Recursion Pharmaceuticals' return on equity of -50.41% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocugen	N/A	-127,987.80%	-115.95%
Recursion Pharmaceuticals	-945.94%	-50.41%	-38.25%

Ocugen has a beta of 2.21, meaning that its share price is 121% more volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market.

Summary

Ocugen beats Recursion Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Ocugen compare to AnaptysBio?

AnaptysBio (NASDAQ:ANAB) and Ocugen (NASDAQ:OCGN) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

AnaptysBio presently has a consensus target price of $82.00, indicating a potential upside of 42.02%. Ocugen has a consensus target price of $9.50, indicating a potential upside of 583.45%. Given Ocugen's higher probable upside, analysts clearly believe Ocugen is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AnaptysBio	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

10.3% of Ocugen shares are held by institutional investors. 31.5% of AnaptysBio shares are held by insiders. Comparatively, 4.0% of Ocugen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, AnaptysBio had 2 more articles in the media than Ocugen. MarketBeat recorded 2 mentions for AnaptysBio and 0 mentions for Ocugen. AnaptysBio's average media sentiment score of 1.12 beat Ocugen's score of 0.00 indicating that AnaptysBio is being referred to more favorably in the media.

Company	Overall Sentiment
AnaptysBio	Positive
Ocugen	Neutral

Ocugen has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%. AnaptysBio's return on equity of 0.00% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AnaptysBio	-11.53%	N/A	-7.75%
Ocugen	N/A	-127,987.80%	-115.95%

AnaptysBio has higher revenue and earnings than Ocugen. AnaptysBio is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AnaptysBio	$234.60M	7.29	-$13.23M	-$1.08	N/A
Ocugen	$4.41M	106.89	-$67.85M	-$0.26	N/A

AnaptysBio has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market. Comparatively, Ocugen has a beta of 2.21, suggesting that its share price is 121% more volatile than the broader market.

Summary

AnaptysBio beats Ocugen on 9 of the 15 factors compared between the two stocks.

Get Ocugen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OCGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OCGN vs. The Competition

Export

Metric	Ocugen	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$471.36M	$4.01B	$7.36B	$12.84B
Dividend Yield	N/A	3.64%	2.54%	11.08%
P/E Ratio	N/A	11.62	272.88	24.24
Price / Sales	106.89	1,350.20	622.17	99.48
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	-34.75	16.80	13.05	6.20
Net Income	-$67.85M	-$12.50M	$3.47B	$348.59M
7 Day Performance	2.96%	3.29%	2.09%	0.08%
1 Month Performance	9.45%	8.23%	6.64%	3.88%
1 Year Performance	37.62%	55.05%	25.02%	16.98%

Ocugen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OCGN Ocugen	1.5949 of 5 stars	$1.39 flat	$9.50 +583.5%	+37.6%	$471.36M	$4.41M	N/A	80
MRNA Moderna	1.6445 of 5 stars	$59.81 +1.1%	$42.13 -29.6%	+434.9%	$23.62B	$1.94B	N/A	4,700	Trending News Analyst Upgrade Options Volume
PFE Pfizer	3.3735 of 5 stars	$27.04 +1.0%	$28.28 +4.6%	+8.4%	$152.52B	$62.58B	35.58	75,000	Trending News Options Volume
IMCR Immunocore	3.6673 of 5 stars	$33.98 -0.1%	$57.29 +68.6%	+12.0%	$1.73B	$400.02M	N/A	320	Analyst Forecast
RXRX Recursion Pharmaceuticals	1.7338 of 5 stars	$3.29 +2.2%	$8.10 +146.2%	-29.1%	$1.71B	$74.68M	N/A	400

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OCGN) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ocugen (OCGN) Competitors